{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:09:32Z","timestamp":1792642172476,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11886-019-1225-6","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T05:02:37Z","timestamp":1574658157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management"],"prefix":"10.1007","volume":"21","author":[{"given":"Chandra K.","family":"Ala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan L.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"15","key":"1225_CR1","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457\u201367. https:\/\/doi.org\/10.1056\/NEJMra1100265.","journal-title":"N Engl J Med"},{"issue":"10","key":"1225_CR2","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","volume":"66","author":"W Li","year":"2015","unstructured":"Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66(10):1160\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.025.","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"1225_CR3","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921\u201364. https:\/\/doi.org\/10.1093\/eurheartj\/ehv318.","journal-title":"Eur Heart J"},{"issue":"5","key":"1225_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa035630","volume":"350","author":"J Sagrista-Sauleda","year":"2004","unstructured":"Sagrista-Sauleda J, Angel J, Sanchez A, Permanyer-Miralda G, Soler-Soler J. Effusive-constrictive pericarditis. N Engl J Med. 2004;350(5):469\u201375. https:\/\/doi.org\/10.1056\/NEJMoa035630.","journal-title":"N Engl J Med"},{"issue":"11","key":"1225_CR5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/circulationaha.116.024041","volume":"136","author":"KK S\u00f8gaard","year":"2017","unstructured":"S\u00f8gaard KK, Farkas DK, Ehrenstein V, Bhaskaran K, B\u00f8tker HE, S\u00f8rensen HT. Pericarditis as a marker of occult cancer and a prognostic factor for cancer mortality. Circulation. 2017;136(11):996\u20131006. https:\/\/doi.org\/10.1161\/circulationaha.116.024041.","journal-title":"Circulation."},{"issue":"9","key":"1225_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrcardio.2017.47","volume":"14","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski JJ, Anavekar NS, Moynihan TJ, Klarich KW. Pathology, imaging, and treatment of cardiac tumours. Nat Rev Cardiol. 2017;14(9):536\u201349. https:\/\/doi.org\/10.1038\/nrcardio.2017.47.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1225_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0167-5273(02)00136-5","volume":"84","author":"Q Meng","year":"2002","unstructured":"Meng Q, Lai H, Lima J, Tong W, Qian Y, Lai S. Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases. Int J Cardiol. 2002;84(1):69\u201375.","journal-title":"Int J Cardiol"},{"key":"1225_CR8","doi-asserted-by":"publisher","unstructured":"Burazor I, Aviel-Ronen S, Imazio M, Markel G, Grossman Y, Yosepovich A, et al. Primary malignancies of the heart and pericardium. Clin Cardiol. 2014. https:\/\/doi.org\/10.1002\/clc.22295.","DOI":"10.1002\/clc.22295"},{"issue":"6","key":"1225_CR9","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1148\/rg.336135512","volume":"33","author":"CS Restrepo","year":"2013","unstructured":"Restrepo CS, Vargas D, Ocazionez D, Martinez-Jimenez S, Betancourt Cuellar SL, Gutierrez FR. Primary pericardial tumors. Radiographics. 2013;33(6):1613\u201330. https:\/\/doi.org\/10.1148\/rg.336135512.","journal-title":"Radiographics."},{"issue":"6","key":"1225_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/1097-0142(19900315)65:6<1456::AID-CNCR2820650634>3.0.CO;2-5","volume":"65","author":"EC Klatt","year":"1990","unstructured":"Klatt EC, Heitz DR. Cardiac metastases. Cancer. 1990;65(6):1456\u20139.","journal-title":"Cancer."},{"issue":"10","key":"1225_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","volume":"35","author":"JD Groarke","year":"2014","unstructured":"Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/eht114.","journal-title":"Eur Heart J"},{"issue":"5","key":"1225_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/cvr\/cvz023","volume":"115","author":"I Raber","year":"2019","unstructured":"Raber I, Asnani A. Cardioprotection in cancer therapy: novel insights with anthracyclines. Cardiovasc Res. 2019;115(5):915\u201321. https:\/\/doi.org\/10.1093\/cvr\/cvz023.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1225_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","volume":"117","author":"SL Galper","year":"2011","unstructured":"Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412\u20138. https:\/\/doi.org\/10.1182\/blood-2010-06-291328.","journal-title":"Blood."},{"issue":"18","key":"1225_CR14","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/circulationaha.114.010376","volume":"130","author":"V Kyto","year":"2014","unstructured":"Kyto V, Sipila J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130(18):1601\u20136. https:\/\/doi.org\/10.1161\/circulationaha.114.010376.","journal-title":"Circulation."},{"issue":"4","key":"1225_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11936-018-0627-x","volume":"20","author":"J Spetz","year":"2018","unstructured":"Spetz J, Moslehi J, Sarosiek K. Radiation-induced cardiovascular toxicity: mechanisms, prevention, and treatment. Curr Treat Options Cardiovasc Med. 2018;20(4):31. https:\/\/doi.org\/10.1007\/s11936-018-0627-x.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"10","key":"1225_CR16","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.amjcard.2013.07.031;10.1016\/j.amjcard.2013.07.031","volume":"112","author":"MS Lee","year":"2013","unstructured":"Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. Am J Cardiol. 2013;112(10):1688\u201396. https:\/\/doi.org\/10.1016\/j.amjcard.2013.07.031;10.1016\/j.amjcard.2013.07.031.","journal-title":"Am J Cardiol"},{"issue":"8","key":"1225_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","volume":"11","author":"MY Desai","year":"2018","unstructured":"Desai MY, Jellis CL, Kotecha R, Johnston DR, Griffin BP. Radiation-associated cardiac disease: A Practical Approach to Diagnosis and Management. JACC Cardiovascular imaging. 2018;11(8):1132\u201349. https:\/\/doi.org\/10.1016\/j.jcmg.2018.04.028.","journal-title":"JACC Cardiovascular imaging"},{"issue":"9","key":"1225_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11886-019-1192-y","volume":"21","author":"N Szpakowski","year":"2019","unstructured":"Szpakowski N, Desai MY. Radiation-associated pericardial disease. Curr Cardiol Rep. 2019;21(9):97. https:\/\/doi.org\/10.1007\/s11886-019-1192-y.","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"1225_CR19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jacc.2003.11.048","volume":"43","author":"SC Bertog","year":"2004","unstructured":"Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol. 2004;43(8):1445\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2003.11.048.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1225_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.athoracsur.2017.05.063","volume":"104","author":"T Murashita","year":"2017","unstructured":"Murashita T, Schaff HV, Daly RC, Oh JK, Dearani JA, Stulak JM, et al. Experience with pericardiectomy for constrictive pericarditis over eight decades. Ann Thorac Surg. 2017;104(3):742\u201350. https:\/\/doi.org\/10.1016\/j.athoracsur.2017.05.063.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"1225_CR21","first-page":"214","volume":"51","author":"N Barbetakis","year":"2010","unstructured":"Barbetakis N, Xenikakis T, Paliouras D, Asteriou C, Samanidis G, Kleontas A, et al. Pericardiectomy for radiation-induced constrictive pericarditis. Hell J Cardiol. 2010;51(3):214\u20138.","journal-title":"Hell J Cardiol"},{"issue":"8","key":"1225_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/ehjci\/jet123","volume":"14","author":"P Lancellotti","year":"2013","unstructured":"Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(8):721\u201340. https:\/\/doi.org\/10.1093\/ehjci\/jet123.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1\u20132","key":"1225_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s002770050312","volume":"75","author":"C Hermans","year":"1997","unstructured":"Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol. 1997;75(1\u20132):55\u20137.","journal-title":"Ann Hematol"},{"issue":"9","key":"1225_CR24","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1001\/archinte.1984.00350210198035","volume":"144","author":"L Vaickus","year":"1984","unstructured":"Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med. 1984;144(9):1868\u20139.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1225_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000072094","volume":"26","author":"A Gahler","year":"2003","unstructured":"Gahler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie. 2003;26(4):348\u201350. https:\/\/doi.org\/10.1159\/000072094.","journal-title":"Onkologie."},{"issue":"2","key":"1225_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0145-2126(94)00123-R","volume":"19","author":"S Reykdal","year":"1995","unstructured":"Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res. 1995;19(2):141\u20134.","journal-title":"Leuk Res"},{"issue":"11","key":"1225_CR27","first-page":"1115","volume":"39","author":"T Yamada","year":"1998","unstructured":"Yamada T, Tsurumi H, Hara T, Sawada M, Oyama M, Moriwaki H. Cytarabine-induced pericarditis. Rinsho Ketsueki. 1998;39(11):1115\u201320.","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"1225_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00228-017-2355-7","volume":"74","author":"X Yang","year":"2018","unstructured":"Yang X, Liu W, Lyons A, Song Z, Zhai S, Hu K. Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report. Eur J Clin Pharmacol. 2018;74(2):181\u20132. https:\/\/doi.org\/10.1007\/s00228-017-2355-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5\u20136","key":"1225_CR29","first-page":"249","volume":"35","author":"W Terpstra","year":"1989","unstructured":"Terpstra W, de Maat CE. Pericardial fibrosis following busulfan treatment. Neth J Med. 1989;35(5\u20136):249\u201352.","journal-title":"Neth J Med"},{"issue":"7","key":"1225_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000093528","volume":"29","author":"J Bock","year":"2006","unstructured":"Bock J, Doenitz A, Andreesen R, Reichle A, Hennemann B. Pericarditis after high-dose chemotherapy: more frequent than expected? Onkologie. 2006;29(7):321\u20134. https:\/\/doi.org\/10.1159\/000093528.","journal-title":"Onkologie."},{"issue":"6","key":"1225_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","volume":"141","author":"JS Gottdiener","year":"1981","unstructured":"Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758\u201363.","journal-title":"Arch Intern Med"},{"issue":"11","key":"1225_CR32","doi-asserted-by":"publisher","first-page":"OE01","DOI":"10.7860\/JCDR\/2015\/15054.6758","volume":"9","author":"S Wadia","year":"2015","unstructured":"Wadia S. Acute cyclophosphamide hemorrhagic myopericarditis: dilemma case report, literature review and proposed diagnostic criteria. J Clin Diagn Res. 2015;9(11):OE01\u2013OE3. https:\/\/doi.org\/10.7860\/JCDR\/2015\/15054.6758.","journal-title":"J Clin Diagn Res"},{"issue":"6","key":"1225_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/sj.bmt.1702592","volume":"26","author":"R Yamamoto","year":"2000","unstructured":"Yamamoto R, Kanda Y, Matsuyama T, Oshima K, Nannya Y, Suguro M, et al. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. Bone Marrow Transplant. 2000;26(6):685\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1702592.","journal-title":"Bone Marrow Transplant"},{"issue":"7950","key":"1225_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/s0140-6736(76)90151-3","volume":"1","author":"F Appelbaum","year":"1976","unstructured":"Appelbaum F, Strauchen JA, Graw RG Jr, Savage DD, Kent KM, Ferrans VJ, et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Lancet. 1976;1(7950):58\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(76)90151-3.","journal-title":"Lancet"},{"issue":"3","key":"1225_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000225128","volume":"33","author":"WJ Durkin","year":"1976","unstructured":"Durkin WJ, Pugh RP, Solomon J, Rosen P, Pajak TF, Bateman JR. Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology. 1976;33(3):140\u20135. https:\/\/doi.org\/10.1159\/000225128.","journal-title":"Oncology."},{"issue":"1","key":"1225_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/1120009X.1990.11738985","volume":"2","author":"R Ben Yosef","year":"1990","unstructured":"Ben Yosef R, Gez E, Catane R. Acute pericarditis following bleomycin: a case report and literature analysis. J Chemother. 1990;2(1):70\u20131.","journal-title":"J Chemother"},{"issue":"6","key":"1225_CR37","first-page":"874","volume":"29","author":"S Tohda","year":"1988","unstructured":"Tohda S, Kobayashi H, Suzuki T, Koyama T, Kamiyama T, Nakamura Y, et al. Acute pericarditis caused by daunorubicin in acute myelocytic leukemia. Rinsho Ketsueki. 1988;29(6):874\u20138.","journal-title":"Rinsho Ketsueki."},{"issue":"7","key":"1225_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1011196910325","volume":"12","author":"H Dazzi","year":"2001","unstructured":"Dazzi H, Kaufmann K, Follath F. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia: analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996. Ann Oncol. 2001;12(7):963\u20136. https:\/\/doi.org\/10.1023\/a:1011196910325.","journal-title":"Ann Oncol"},{"issue":"23","key":"1225_CR39","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.115.010484","volume":"132","author":"AM Bellinger","year":"2015","unstructured":"Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. 2015;132(23):2248\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.010484.","journal-title":"Circulation."},{"issue":"35","key":"1225_CR40","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.62.4718.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1225_CR41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1517\/14740331003742935","volume":"9","author":"M Breccia","year":"2010","unstructured":"Breccia M, Alimena G. Pleural\/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Saf. 2010;9(5):713\u201321. https:\/\/doi.org\/10.1517\/14740331003742935.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1225_CR42","doi-asserted-by":"publisher","first-page":"Fd03","DOI":"10.7860\/jcdr\/2017\/24633.9418","volume":"11","author":"S Wattal","year":"2017","unstructured":"Wattal S, Rao MS, Chandra GN, Razak UK, Shetty KR. Dasatinib induced cardiac tamponade-a rare association. J Clin Diagn Res. 2017;11(2):Fd03\u2013fd4. https:\/\/doi.org\/10.7860\/jcdr\/2017\/24633.9418.","journal-title":"J Clin Diagn Res"},{"issue":"1","key":"1225_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-0609.2004.00347.x","volume":"74","author":"M Breccia","year":"2005","unstructured":"Breccia M, D'Elia GM, D'Andrea M, Latagliata R, Alimena G. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol. 2005;74(1):89\u201390. https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00347.x.","journal-title":"Eur J Haematol"},{"issue":"2","key":"1225_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ajh.10186","volume":"71","author":"JC Barton","year":"2002","unstructured":"Barton JC, Jones SC, Lamberth WC, Reymann MT, Scott VC. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol. 2002;71(2):139\u201340. https:\/\/doi.org\/10.1002\/ajh.10186.","journal-title":"Am J Hematol"},{"issue":"6","key":"1225_CR45","first-page":"529","volume":"44","author":"S Miura","year":"2017","unstructured":"Miura S, Murase K, Sakurada A, Takada K, Iyama S, Sato T, et al. A case of chronic myelogenous leukemia that developed fibrous pericarditis owing to nilotinib use. Gan To Kagaku Ryoho. 2017;44(6):529\u201331.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"1225_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/jcm8020143","volume":"8","author":"Gwang Jeong","year":"2019","unstructured":"Jeong GH, Lee KH, Lee IR, Oh JH, Kim DW, Shin JW, et al. Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J Clin Med. 2019;8(2). https:\/\/doi.org\/10.3390\/jcm8020143.","journal-title":"Journal of Clinical Medicine"},{"issue":"4","key":"1225_CR47","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/01.cir.87.4.1340","volume":"87","author":"J Zhang","year":"1993","unstructured":"Zhang J, Yu ZX, Hilbert SL, Yamaguchi M, Chadwick DP, Herman EH, et al. Cardiotoxicity of human recombinant interleukin-2 in rats. A morphological study. Circulation. 1993;87(4):1340\u201353. https:\/\/doi.org\/10.1161\/01.cir.87.4.1340.","journal-title":"Circulation."},{"issue":"10","key":"1225_CR48","first-page":"3075","volume":"8","author":"MB Atkins","year":"2002","unstructured":"Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002;8(10):3075\u201381.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1225_CR49","first-page":"484","volume":"81","author":"S Fava","year":"1996","unstructured":"Fava S, Luoni M, Stioui S. Pericarditis during interferon-alpha therapy in chronic myelogenous leukemia. Haematologica. 1996;81(5):484.","journal-title":"Haematologica."},{"issue":"6","key":"1225_CR50","first-page":"486","volume":"9","author":"O Benjamini","year":"2007","unstructured":"Benjamini O, Kimhi O, Lishner M. Severe pleuropericarditis and cardiomyopathy induced by high dose interferon alpha-2b. Isr Med Assoc J. 2007;9(6):486\u20137.","journal-title":"Isr Med Assoc J"},{"issue":"6382","key":"1225_CR51","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science."},{"issue":"1","key":"1225_CR52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","volume":"29","author":"J Tang","year":"2018","unstructured":"Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84\u201391. https:\/\/doi.org\/10.1093\/annonc\/mdx755.","journal-title":"Ann Oncol"},{"issue":"18","key":"1225_CR53","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214.","journal-title":"N Engl J Med"},{"issue":"12","key":"1225_CR54","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"\u2022 Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9 This observational study gives an overview of cardiovascular adverse events reported with immune checkpoint inhibitors.","journal-title":"Lancet Oncol"},{"issue":"10124","key":"1225_CR55","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6.","journal-title":"Lancet."},{"issue":"16","key":"1225_CR56","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"key":"1225_CR57","doi-asserted-by":"publisher","unstructured":"De Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. J Immunother. 2018. https:\/\/doi.org\/10.1097\/CJI.0000000000000217.","DOI":"10.1097\/CJI.0000000000000217"},{"key":"1225_CR58","doi-asserted-by":"publisher","first-page":"794842","DOI":"10.1155\/2015\/794842","volume":"2015","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842. https:\/\/doi.org\/10.1155\/2015\/794842.","journal-title":"Case Rep Oncol Med"},{"key":"1225_CR59","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ijcard.2016.08.023","volume":"222","author":"J Nesfeder","year":"2016","unstructured":"Nesfeder J, Elsensohn AN, Thind M, Lennon J, Domsky S. Pericardial effusion with tamponade physiology induced by nivolumab. Int J Cardiol. 2016;222:613\u20134. https:\/\/doi.org\/10.1016\/j.ijcard.2016.08.023.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1225_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000447053","volume":"136","author":"I Kushnir","year":"2017","unstructured":"Kushnir I, Wolf I. Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology. 2017;136(1):49\u201351. https:\/\/doi.org\/10.1159\/000447053.","journal-title":"Cardiology."},{"issue":"5","key":"1225_CR61","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"Jiun-Ruey Hu","year":"2019","unstructured":"\u2022\u2022 Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019. https:\/\/doi.org\/10.1093\/cvr\/cvz026 This review gives an overview, discusses the pathophysiology, and significance of cardiovascular adverse effects of immune checkpoint inhibitors.","journal-title":"Cardiovascular Research"},{"issue":"1","key":"1225_CR62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/08998280.2005.11928030","volume":"18","author":"WC Roberts","year":"2005","unstructured":"Roberts WC. Pericardial heart disease: its morphologic features and its causes. Proc (Bayl Univ Med Cent). 2005;18(1):38\u201355. https:\/\/doi.org\/10.1080\/08998280.2005.11928030.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"11","key":"1225_CR63","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jcmg.2011.08.011","volume":"4","author":"AO Zurick","year":"2011","unstructured":"Zurick AO, Bolen MA, Kwon DH, Tan CD, Popovic ZB, Rajeswaran J, et al. Pericardial delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis undergoing surgical pericardiectomy: a case series with histopathological correlation. JACC Cardiovascular imaging. 2011;4(11):1180\u201391. https:\/\/doi.org\/10.1016\/j.jcmg.2011.08.011.","journal-title":"JACC Cardiovascular imaging"},{"issue":"6","key":"1225_CR64","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","volume":"14","author":"M Altan","year":"2019","unstructured":"Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, et al. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol. 2019;14(6):1102\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.026.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1225_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017;5(1):91. https:\/\/doi.org\/10.1186\/s40425-017-0296-4.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1225_CR66","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911\u201339. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012.","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"1225_CR67","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.echo.2013.06.023","volume":"26","author":"AL Klein","year":"2013","unstructured":"Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013;26(9):965\u20131012 e15. https:\/\/doi.org\/10.1016\/j.echo.2013.06.023.","journal-title":"J Am Soc Echocardiogr"},{"issue":"15","key":"1225_CR68","doi-asserted-by":"publisher","first-page":"e3273","DOI":"10.1097\/md.0000000000003273","volume":"95","author":"G Numico","year":"2016","unstructured":"Numico G, Cristofano A, Occelli M, Sicuro M, Mozzicafreddo A, Fea E, et al. Prolonged drainage and intrapericardial bleomycin administration for cardiac tamponade secondary to cancer-related pericardial effusion. Medicine (Baltimore). 2016;95(15):e3273. https:\/\/doi.org\/10.1097\/md.0000000000003273.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1225_CR69","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.bjc.6604866","volume":"100","author":"H Kunitoh","year":"2009","unstructured":"Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, et al. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009;100(3):464\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6604866.","journal-title":"Br J Cancer"},{"issue":"1","key":"1225_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/JTO.0b013e31802c8260","volume":"2","author":"R Maruyama","year":"2007","unstructured":"Maruyama R, Yokoyama H, Seto T, Nagashima S, Kashiwabara K, Araki J, et al. Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial. J Thorac Oncol. 2007;2(1):65\u20138. https:\/\/doi.org\/10.1097\/JTO.0b013e31802c8260.","journal-title":"J Thorac Oncol"},{"key":"1225_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0104-y","volume":"7","author":"S Shaheen","year":"2018","unstructured":"Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol. 2018;7:11. https:\/\/doi.org\/10.1186\/s40164-018-0104-y.","journal-title":"Exp Hematol Oncol"},{"issue":"18","key":"1225_CR72","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","volume":"316","author":"A Brucato","year":"2016","unstructured":"Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906\u201312. https:\/\/doi.org\/10.1001\/jama.2016.15826.","journal-title":"JAMA."},{"issue":"2","key":"1225_CR73","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jtcvs.2016.03.098","volume":"152","author":"EA Gillaspie","year":"2016","unstructured":"Gillaspie EA, Stulak JM, Daly RC, Greason KL, Joyce LD, Oh J, et al. A 20-year experience with isolated pericardiectomy: analysis of indications and outcomes. J Thorac Cardiovasc Surg. 2016;152(2):448\u201358. https:\/\/doi.org\/10.1016\/j.jtcvs.2016.03.098.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"1225_CR74","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/thx.43.8.637","volume":"43","author":"VV Bashi","year":"1988","unstructured":"Bashi VV, John S, Ravikumar E, Jairaj PS, Shyamsunder K, Krishnaswami S. Early and late results of pericardiectomy in 118 cases of constrictive pericarditis. Thorax. 1988;43(8):637\u201341.","journal-title":"Thorax."},{"issue":"17","key":"1225_CR75","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1225-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T19:20:12Z","timestamp":1606159212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1225-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1225-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"25 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Chandra K. Ala declares no conflict of interest.Allan L. Klein reports he is on the steering committee for Sobi and Pfizer, and he is also supported by a research grant from Kiniksa.Javid J. Moslehi reports he has been a consultant for Pfzier, Novartis, Bristol-Myers Squibb, Audentes, AstraZeneca, and Nektar.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"156"}}